|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Ann Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu L, Li H, Chen L, Ma X, Gao Y, Li X,
Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular
signatures in renal cell carcinoma: A systematic review and
meta-analysis. Oncotarget. 6:32545–32560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Zhang D, Yi C, Wang Y, Wang H and
Wang J: MicroRNA-22 functions as a tumor suppressor by targeting
SIRT1 in renal cell carcinoma. Oncol Rep. 35:559–567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jingushi K, Ueda Y, Kitae K, Hase H, Egawa
H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et
al: miR-629 Targets TRIM33 to Promote TGFβ/Smad Signaling and
Metastatic Phenotypes in ccRCC. Mol Cancer Res. 13:565–574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ucar A, Vafaizadeh V, Jarry H, Fiedler J,
Klemmt PA, Thum T, Groner B and Chowdhury K: miR-212 and miR-132
are required for epithelial stromal interactions necessary for
mouse mammary gland development. Nat Genet. 42:1101–1108. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Incoronato M, Urso L, Portela A, Laukkanen
MO, Soini Y, Quintavalle C, Keller S, Esteller M and Condorelli G:
Epigenetic regulation of miR-212 expression in lung cancer. PLoS
One. 6:e277222011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Y, Jia D, Kim H, Elmageed Abd ZY,
Datta A, Davis R, Srivastav S, Moroz K, Crawford BE, Moparty K, et
al: Dysregulation of miR-212 promotes castration resistance through
hnRNPH1-Mediated regulation of AR and AR-V7: Implications for
racial disparity of prostate cancer. Clin Cancer Res. 22:1744–1756.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao JL, Zhang L, Guo X, Wang JH, Zhou W,
Liu M, Li X and Tang H: miR-212/132 downregulates SMAD2 expression
to suppress the G1/S phase transition of the cell cycle and the
epithelial to mesenchymal transition in cervical cancer cells.
IUBMB Life. 67:380–394. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Li C, Shen C, Yin F, Wang K, Liu Y,
Zheng B, Zhang W, Hou X, Chen X, et al: MiR-212-3p inhibits
glioblastoma cell proliferation by targeting SGK3. J Neurooncol.
122:431–439. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei LQ, Liang HT, Qin DC, Jin HF, Zhao Y
and She MC: MiR-212 exerts suppressive effect on SKOV3 ovarian
cancer cells through targeting HBEGF. Tumour Biol. 35:12427–12434.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang JL, Liao Y, Qiu MX, Li J and An Y:
Long non-coding RNA CCAT2 promotes cell proliferation and invasion
through regulating Wnt/β-catenin signaling pathway in clear cell
renal cell carcinoma. Tumour Biol. 39:10104283177113142017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu J, Cui L, Xu A, Yin X, Li F and Gao J:
MEIS1 inhibits clear cell renal cell carcinoma cells proliferation
and in vitro invasion or migration. BMC Cancer. 17:1762017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Furge KA, Chen J, Koeman J, Swiatek P,
Dykema K, Lucin K, Kahnoski R, Yang XJ and Teh BT: Detection of DNA
copy number changes and oncogenic signaling abnormalities from gene
expression data reveals MYC activation in high-grade papillary
renal cell carcinoma. Cancer Res. 67:3171–3176. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tu H, Wei G, Cai Q, Chen X, Sun Z, Cheng
C, Zhang L, Feng Y, Zhou H, Zhou B and Zeng T: MicroRNA-212
inhibits hepatocellular carcinoma cell proliferation and induces
apoptosis by targeting FOXA1. OncoTargets Ther. 8:2227–2235.
2015.
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiping Z, Ming F, Lixiang W, Xiuming L,
Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C and Jihui
J: MicroRNA-212 inhibits proliferation of gastric cancer by
directly repressing retinoblastoma binding protein 2. J Cell
Biochem. 114:2666–2672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meng X, Wu J, Pan C, Wang H, Ying X, Zhou
Y, Yu H, Zuo Y, Pan Z, Liu RY and Huang W: Genetic and epigenetic
down-regulation of microRNA-212 promotes colorectal tumor
metastasis via dysregulation of MnSOD. Gastroenterology.
145(426–436): e1–e6. 2013.
|
|
27
|
Bernardo GM and Keri RA: FOXA1: A
transcription factor with parallel functions in development and
cancer. Biosci Rep. 32:113–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Neely BA, Wilkins CE, Marlow LA,
Malyarenko D, Kim Y, Ignatchenko A, Sasinowska H, Sasinowski M,
Nyalwidhe JO, Kislinger T, et al: Proteotranscriptomic analysis
reveals stage specific changes in the molecular landscape of
clear-cell renal cell carcinoma. PLoS One. 11:e01540742016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shou J, Lai Y, Xu J and Huang J:
Prognostic value of FOXA1 in breast cancer: A systematic review and
meta-analysis. Breast. 27:35–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang YA and Yu J: Current perspectives on
FOXA1 regulation of androgen receptor signaling and prostate
cancer. Genes Dis. 2:144–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ren H, Zhang P, Tang Y, Wu M and Zhang W:
Forkhead box protein A1 is a prognostic predictor and promotes
tumor growth of gastric cancer. OncoTargets Ther. 8:3029–3039.
2015.
|
|
32
|
Augello MA, Hickey TE and Knudsen KE:
FOXA1: Master of steroid receptor function in cancer. EMBO J.
30:3885–3894. 2011. View Article : Google Scholar : PubMed/NCBI
|
